Japanese Encephalitis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H2 2016, provides an overview of the Japanese Encephalitis (Central Nervous System) pipeline landscape.

Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. Treatment targets relief of symptoms like pain relievers and anticonvulsants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Japanese Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Japanese Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 1, 5, 3 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Japanese Encephalitis.

Japanese Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Japanese Encephalitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Japanese Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Japanese Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Japanese Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Japanese Encephalitis (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Japanese Encephalitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Japanese Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Japanese Encephalitis Overview 7
Therapeutics Development 8
Pipeline Products for Japanese Encephalitis - Overview 8
Pipeline Products for Japanese Encephalitis - Comparative Analysis 9
Japanese Encephalitis - Therapeutics under Development by Companies 10
Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes 11
Japanese Encephalitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Japanese Encephalitis - Products under Development by Companies 16
Japanese Encephalitis - Products under Investigation by Universities/Institutes 17
Japanese Encephalitis - Companies Involved in Therapeutics Development 18
Ennaid Therapeutics, LLC 18
Indian Immunologicals Limited 19
Kineta, Inc. 20
Livzon Pharmaceutical Group Inc. 21
Panacea Biotec Limited 22
Vaxine Pty Ltd 23
Zydus Cadila Healthcare Limited 24
Japanese Encephalitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
FDX-000 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Japanese encephalitis vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Japanese encephalitis vaccine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Japanese encephalitis vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Japanese encephalitis vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Japanese encephalitis vaccine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Japanese encephalitis vaccine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Japanese encephalitis vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Japanese encephalitis vaccine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Japanese encephalitis vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
KIN-1400 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Synthetic Peptides for Japanese Encephalitis - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Japanese Encephalitis - Dormant Projects 46
Japanese Encephalitis - Discontinued Products 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Number of Products under Development for Japanese Encephalitis, H2 2016 8
Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Comparative Analysis by Unknown Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Japanese Encephalitis - Pipeline by Ennaid Therapeutics, LLC, H2 2016 18
Japanese Encephalitis - Pipeline by Indian Immunologicals Limited, H2 2016 19
Japanese Encephalitis - Pipeline by Kineta, Inc., H2 2016 20
Japanese Encephalitis - Pipeline by Livzon Pharmaceutical Group Inc., H2 2016 21
Japanese Encephalitis - Pipeline by Panacea Biotec Limited, H2 2016 22
Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H2 2016 23
Japanese Encephalitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Japanese Encephalitis - Dormant Projects, H2 2016 46
Japanese Encephalitis - Discontinued Products, H2 2016 47